Episode
E353: Why Biotech Is Struggling in Today’s Market (and the Future of Healthcare)
- Published
- Apr 22, 2026
- Duration seconds
- 1993
- Processing state
not_requested- Canonical source
- https://howiinvestpodcast.com/episodes/0PVrTGdgCLi
Actions
POST https://stenobird.com/v1/public/podcasts/how-i-invest-with-david-weisburd-6470713/episodes/e353-why-biotech-is-struggling-in-today-s-market-and-the-future-of-healthcare/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/how-i-invest-with-david-weisburd-6470713/e353-why-biotech-is-struggling-in-today-s-market-and-the-future-of-healthcare.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
What if the biggest opportunity in healthcare isn’t new drugs—but reinventing how the entire system works? In this episode, I sit down with David Berry, Founder of over 20 companies including seven $1B+ businesses, to discuss why the traditional biotech model is breaking and where the next wave of innovation in healthcare is emerging. David explains how pricing pressure, rising costs, and global competition are compressing returns in drug development, while AI, data, and new business models are unlocking entirely new ways to deliver care. We also explore how technology is transforming clinical trials, why healthcare is shifting beyond pharmaceuticals, and how investors can find opportunity in mispriced parts of the market.